Search research articles
Contact Us
Filters
Showing results (121-130 of 174) with videos related to
Page
of 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 18, 2012
Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer
Michael J Fisch, Ju-Whei Lee, Matthias Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2022
Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials
Joseph M Unger, Riha Vaidya, Kathy S Albain, et al.
Breast Cancer Research and Treatment
|
August 31, 2018
Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927)
Sherry Shen, Joseph M Unger, Katherine D Crew, et al.
Gynecologic Oncology
|
August 5, 2020
Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment
Jung-Min Lee, Christina M Annunziata, John L Hays, et al.
Clinical Trials (London, England)
|
December 1, 2005
Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Elise D Cook, Sarah Moody-Thomas, Karen B Anderson, et al.
CA: a Cancer Journal for Clinicians
|
March 22, 2024
Cancer screening with multicancer detection tests: A translational science review
Wendy S Rubinstein, Christos Patriotis, Anthony Dickherber, et al.
Journal of the National Cancer Institute
|
July 12, 2013
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial
Theodore M Brasky, Amy K Darke, Xiaoling Song, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 6, 2015
Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927
Dawn L Hershman, Joseph M Unger, Katherine D Crew, et al.
Cancer Epidemiology
|
June 25, 2018
The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials
Joseph M Unger, William E Barlow, Catherine M Tangen, et al.
The New England Journal of Medicine
|
May 28, 2004
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter
Ian M Thompson, Donna K Pauler, Phyllis J Goodman, et al.
Page
of 18
Search research articles
Search
Showing results (121-130 of 174) with videos related to
Sort By:
Page
of 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 18, 2012
Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer
Michael J Fisch, Ju-Whei Lee, Matthias Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2022
Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials
Joseph M Unger, Riha Vaidya, Kathy S Albain, et al.
Breast Cancer Research and Treatment
|
August 31, 2018
Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927)
Sherry Shen, Joseph M Unger, Katherine D Crew, et al.
Gynecologic Oncology
|
August 5, 2020
Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment
Jung-Min Lee, Christina M Annunziata, John L Hays, et al.
Clinical Trials (London, England)
|
December 1, 2005
Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Elise D Cook, Sarah Moody-Thomas, Karen B Anderson, et al.
CA: a Cancer Journal for Clinicians
|
March 22, 2024
Cancer screening with multicancer detection tests: A translational science review
Wendy S Rubinstein, Christos Patriotis, Anthony Dickherber, et al.
Journal of the National Cancer Institute
|
July 12, 2013
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial
Theodore M Brasky, Amy K Darke, Xiaoling Song, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 6, 2015
Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927
Dawn L Hershman, Joseph M Unger, Katherine D Crew, et al.
Cancer Epidemiology
|
June 25, 2018
The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials
Joseph M Unger, William E Barlow, Catherine M Tangen, et al.
The New England Journal of Medicine
|
May 28, 2004
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter
Ian M Thompson, Donna K Pauler, Phyllis J Goodman, et al.
Page
of 18